Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Firibastat versus ramipril after acute anterior myocardial infarction
2018-003146-17Phase 2Completed
- Sponsor
- Quantum Genomics
- Start
- Feb 2019
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, double-blind trial of firibastat and ramipril in myocardial infarction (MI) and left ventricular dysfunction (2 arms), sponsored by Quantum Genomics. Primary endpoint: Change from Baseline to Day 84 in left ventricular ejection fraction. Started Feb 2019; status: completed.
02
Drugs
firibastatramipril
03
Conditions
myocardial infarction (MI)left ventricular dysfunction
Beyond the preview
Go deeper on 2018-003146-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003146-17.